Nordic-Baltic-British left main revascularisation study

INTERVENTION: 1. Coronary artery bypass surgery 2. Percutaneous coronary angioplasty with drug eluting stent Follow up length: 60 months Study entry: single randomisation only Contact details for patient information sheet: Cardiac Research Unit Sussex House 1 Abbey Road Brighton BN2 1ES United Kingdom CONDITION: Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular ; Circulatory System ; Stenosis PRIMARY OUTCOME: 1. Combined endpoint of death, stroke, non‐index treatment related myocardioal infarction (MI) and new revascularisation (PCI or CABG) after 2 years; 2. Death after 5 years SECONDARY OUTCOME: 1. Combined endpoint of death, stroke and non‐index treatment related MI after 1 month and after 1, 2, 3 and 4 years; 2. Individual endpoints of death, stroke and non‐index treatment related MI after 1 month and after 1, 2, 3, 4 and 5 years; 3. New revascularisation by CABG or PCI after 1, 2, 3, 4 and 5 years; 4. Death after 10 years; 5. Definite stent thrombosis/symptomatic graft occlusion; 6. Canadian Cardiovascular Society (CCS) angina score; 7. New York Heart Association (NYHA) functional class; 8. Duration of admission for index treatment INCLUSION CRITERIA: 1. Stable, unstable angina pectoris or acute coronary syndrome (ACS) 2. Significant lesion* of left main coronary artery (LMCA) ostium, mid‐shaft and/or bifurcation and with no more than three additional non‐complex** percutaneous coronary intervention (PCI) lesions 3. Patient eligible to be treated by coronary artery bypass graft (CABG) and by PCI 4. Signed informed consent *Visually assessed diameter stenosis greater than 50% or fractional flow reserve less than 0.80 **Length less than 25 mm, non‐CTO, non‐2‐stent bifurcation, non‐calcified and non‐tortuous vessel morphology coronary lesion